Joan M. Stilling, Oury Monchi, Farnaz Amoozegar, Chantel T. Debert January 23, 2019


Headache is among the most prevalent causes of disability worldwide. Non‐pharmacologic interventions, including neuromodulation therapies, have been proposed in patients who are treatment resistant or intolerant to medications.


To perform a systematic review on the use of transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) for the treatment of specific headache disorders (ie, migraine, tension, cluster, posttraumatic).… Read More...

Serena L. Orr, Abigail Turner, Marielle A. Kabbouche, Paul S. Horn, Hope L. O’Brien, Joanne Kacperski, Susan LeCates, Shannon White, Jessica Weberding, Mimi N. Miller, Scott W. Powers, Andrew D. Hershey January 23, 2019


To characterize the short‐term prognosis of a clinical population of pediatric and young adult patients with migraine and explore predictors of clinical worsening while in care.


This was a retrospective study of all migraine patients seen at the Cincinnati Children’s Hospital Headache Center from 09/01/2006 to 12/31/2017, who had at least 1 follow‐up visit within 1‐3 months of the index visit analyzed.… Read More...

Felipe Araujo Andrade Oliveira, Pedro Augusto Sampaio Rocha‐Filho January 22, 2019


Although headaches attributed to ischemic strokes and transient ischemic attack occur frequently, they are often overlooked and underdiagnosed as manifestations of cerebrovascular disease.


This is a narrative review.


The prevalence of headache attributed to ischemic stroke varies between 7.4% and 34% of cases and of headache attributed to transient ischemic attack, from 26% to 36%.… Read More...

X. Michelle Androulakis, Souvik Sen, Nishanth Kodumuri, Tianming Zhang, John Grego, Wayne Rosamond, Rebecca F. Gottesman, Eyal Shahar, B. Lee Peterlin January 21, 2019

Background and Purpose

To evaluate the association between cumulative exposure to migraine and incidence of ischemic stroke in the Atherosclerosis Risk in Communities (ARIC) study.


In this ongoing, prospective longitudinal community‐based cohort, participants were interviewed to ascertain migraine history at the third visit (1993–1995), followed for ischemic stroke incidence over 20 years.… Read More...

Stephen B. Shrewsbury, Maria Jeleva, Kelsey H. Satterly, Jason Lickliter, John Hoekman January 19, 2019


Investigate the safety and pharmacokinetics (PK) of INP104, intranasal dihydroergotamine mesylate (DHE) administered via a Precision Olfactory Delivery (POD®) device, (Impel NeuroPharma, Seattle, WA) vs intravenous (IV) DHE and DHE nasal spray (Migranal®) in healthy adult subjects.… Read More...

Mario F.P. Peres, Arão Belitardo Oliveira, Juliane P. Mercante, Helder H. Kamei, Patricia R. Tobo, Todd D. Rozen, Morris Levin, Dawn C. Buse, Giancarlo Lucchetti January 19, 2019


Optimism and pessimism are related to several mental health and brain disorders, are significant predictors of physical and psychological health outcomes, and implicated as psychosocial determinants of the pain experience. Despite this promising evidence, limited information is available on optimism and pessimism in headache disorders.… Read More...

Alicia Gonzalez‐Martinez, Daniel Romero‐Palacián, Julio Dotor García‐Soto, Pedro Sánchez, Gemma Reig Roselló, Gustavo Zapata Wainberg January 18, 2019


To report a case of reversible cerebral vasoconstriction syndrome (RCVS) possibly precipitated by tocilizumab.


Immunosuppressant drugs are a rare cause of reversible cerebral vasoconstriction, a syndrome characterized by segmental vasospasm. However, although it is considered a reversible process that resolves within 3 months, the cerebral vasoconstriction over time may lead to severe complications such as strokes.… Read More...

Kai‐Uwe Kern, Myriam Schwickert‐Nieswandt, Christian Maihöfner, Charly Gaul January 18, 2019


Trigeminal neuralgia is difficult to treat and shows upregulation of sodium channels. The expectorant ambroxol acts as a strong local anesthetic, about 40 times stronger than lidocaine. It preferentially inhibits the channel subtype Nav1.8, expressed especially in nociceptive C‐fibers.… Read More...

Andoird App